Počet záznamů: 1
Omega-3 phospholipids and obesity-associated NAFLD: Potential mechanisms and therapeutic perspectives
- 1.
SYSNO ASEP 0555820 Druh ASEP J - Článek v odborném periodiku Zařazení RIV J - Článek v odborném periodiku Poddruh J Článek ve WOS Název Omega-3 phospholipids and obesity-associated NAFLD: Potential mechanisms and therapeutic perspectives Tvůrce(i) Mitrović, Marko (FGU-C) ORCID
Sistilli, Gabriella (FGU-C) ORCID, RID
Horáková, Olga (FGU-C) RID, ORCID
Rossmeisl, Martin (FGU-C) RID, ORCIDČíslo článku e13650 Zdroj.dok. European Journal of Clinical Investigation. - : Wiley - ISSN 0014-2972
Roč. 52, č. 3 (2022)Poč.str. 19 s. Jazyk dok. eng - angličtina Země vyd. US - Spojené státy americké Klíč. slova krill oil ; marine phospholipids ; n-3 polyunsaturated fatty acids ; non-alcoholic fatty liver disease ; obesity Obor OECD Endocrinology and metabolism (including diabetes, hormones) CEP GA17-11027S GA ČR - Grantová agentura ČR Způsob publikování Omezený přístup Institucionální podpora FGU-C - RVO:67985823 UT WOS 000679928600001 EID SCOPUS 85111860948 DOI https://doi.org/10.1111/eci.13650 Anotace Prevalence of non-alcoholic fatty liver disease (NAFLD) increases in line with obesity and type 2 diabetes, and there is no approved drug therapy. Polyunsaturated fatty acids of n-3 series (omega-3) are known for their hypolipidaemic and anti-inflammatory effects. Existing clinical trials suggest varying effectiveness of triacylglycerol- or ethyl ester-bound omega-3 in the treatment of NAFLD, without affecting advanced stages such as non-alcoholic steatohepatitis. Preclinical studies suggest that the lipid class used to supplement omega-3 may determine the extent and nature of their effects on metabolism. Phospholipids of marine origin represent an alternative source of omega-3. The aim of this review is to summarise the available evidence on the use of omega-3 phospholipids, primarily in obesity-related NAFLD, and to outline perspectives of their use in the prevention/treatment of NAFLD. A PubMed literature search was conducted in May 2021. In total, 1088 articles were identified, but based on selection criteria, 38 original papers were included in the review. Selected articles describing the potential mechanisms of action of omega-3 phospholipids have also been included. Preclinical evidence clearly indicates that omega-3 phospholipids have strong antisteatotic effects in the liver, which are stronger compared to omega-3 administered as triacylglycerols. Multiple mechanisms are likely involved in the overall antisteatotic effects, involving not only the liver but also adipose tissue and the gut. Robust preclinical evidence for strong antisteatotic effects of omega-3 phospholipids in the liver should be confirmed in clinical trials. Further research is needed on the possible effects of omega-3 phospholipids on advanced NAFLD. Pracoviště Fyziologický ústav Kontakt Lucie Trajhanová, lucie.trajhanova@fgu.cas.cz, Tel.: 241 062 400 Rok sběru 2023 Elektronická adresa https://doi.org/10.1111/eci.13650
Počet záznamů: 1